Premium
Glutamate receptor, ionotropic, kainate 2 silencing by DNA hypermethylation possesses tumor suppressor function in gastric cancer
Author(s) -
Wu ChiSheng,
Lu YenJung,
Li HsinPai,
Hsueh Chuen,
Lu ChangYi,
Leu YuWei,
Liu HaoPing,
Lin KwangHuei,
HuiMing Huang Tim,
Chang YuSun
Publication year - 2010
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.24958
Subject(s) - kainate receptor , ionotropic effect , cancer , dna methylation , function (biology) , suppressor , cancer research , gene silencing , biology , genetics , chemistry , glutamate receptor , ampa receptor , receptor , gene , gene expression
Abstract Aberrant DNA methylation is considered a major mechanism for silencing tumor suppressor genes in gastric cancer. We used CpG microarray and differential methylation hybridization strategies to identify potential tumor suppressor genes and recovered glutamate receptor, ionotropic, kainate 2 (GRIK2) as a novel epigenetic target in gastric cancer. Additional experiments showed that the promoter region of GRIK2 was hypermethylated in 3 of the 4 tested gastric cancer cell lines, and its expression was restored by treatment of cells with the DNA methylation inhibitor, 5′‐aza‐dC. In clinical samples, the GRIK2 promoter was differentially hypermethylated in tumor tissues compared with adjacent normal tissues ( p < 0.001), and this methylation was inversely correlated with the expression level of GRIK2 mRNA ( r = −0.44). Functional studies further showed that GRIK2‐expressing gastric cancer cell lines showed decreased colony formation and cell migration. Taken together, these results suggest that GRIK2 may play a tumor‐suppressor role in gastric cancer. Future studies are warranted to examine whether DNA hypermethylation of the GRIK2 promoter can be used as a potential tumor marker for gastric cancer.